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ABSTRACT  
THE EFFECTS OF POST-OPERATIVE ANALGESICS ON OVARIAN MEDULLARY 
ANGIOGENSIS AND VASCULOGENESIS  
 
by Shamus M. Brady  
A critical factor for successful ovarian transplantation is the expeditious 
establishment of sufficient blood supply. Recommendations intended to improve recovery, 
reduce the effects of stress, and decrease the amount of pain for laboratory animals 
undergoing surgical procedures include post-operative analgesia. The two main types of 
drugs that are recommended for pain management are opioids and non-steroidal anti-
inflammatory drugs (NSAIDs). Buprenorphine, an opioid, and meloxicam, an NSAID, are 
both widely used and have been shown to affect angiogenesis and vasculogenesis. This study 
was designed to examine the influence meloxicam and buprenorphine had on new blood 
vessel formation in the ovarian medullary region of aged female recipient CBA/J mice, 
transplanted with young ovaries from CBA/J donor females. Medullary vessel analysis was 
performed by viewing 40 µm thick sections fluorescently labelled with the cell marker 
CD31/PECAM-1 via confocal microscopy. A multivariate analysis of variance (MANOVA) 
was performed between treatment groups to analyze how the independent variables of 
analgesic administration affected multiple dependent variables of deep microvessel 
quantities. Results demonstrated no significant endothelial microvessel growth or reduction 
among the meloxicam or buprenorphine-treated mice as compared to saline-treated mice. 
Results further suggested that neither type of analgesic drugs affected medullary ovarian 
angiogenesis and vasculogenesis after ovarian transplantation of young ovaries into aged 
females. 
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Introduction 
The mammalian ovary performs two major functions: the production of germ 
cells (oocytes), and synthesis of signaling molecules such as the steroid hormones 
estrogen and progestins as well as peptide growth factors (Edson, Nagaraja, & Matzuk, 
2009). These signal molecules are part of an endocrine axis known as the hypothalamic-
pituitary-ovarian axis, responsible for the production of germ cells as well as 
development of secondary sex characteristics (Edson et al., 2009). The axis originates in 
the hypothalamus, projects a short distance to the anterior pituitary, and circulates a 
longer distance to the ovary (Ginther, Dierschke, Walsh, & Del Campo, 1974). The 
ovarian artery enters the ovary through the hilus or stalk and is initially localized deep 
into the medullary stroma, the tissue consisting of blood vessels and connective tissue 
that provides the structural support for the developing follicles (Brown and Russell, 
2013). The artery divides into several branches that run within the deep medullary region, 
separating into many afferent arterioles and capillaries (Kikuta, Macchiarelli, & 
Murakami, 1991; Courbiere et al., 2009). The medullary afferent arterioles eventually 
branch at the superficial cortex region to form capillary plexuses (Kikuta et al., 1991). 
The vasculature between the cortical and medullary regions of the ovary differs in 
structure and function. The arteries in the medulla are larger in size and highly tortuous, 
and the vasculature within the cortex includes arterioles and primary capillary beds 
(Kikuta et al., 1991).  The cortical capillary beds provide nutrients and oxygen, while 
facilitating CO2 and waste removal from follicles ranging from primordial to developing 
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primary and secondary follicles that have the potential to develop into a mature ovum 
(Fortune, Cushman, Wahl, & Kito, 2000; Brown and Russell, 2013). 
Blood vessels are initially formed in the embryo via angiogenesis and 
vasculogenesis (Bussolino, Mantovani, & Persico, 1997). Angiogenesis is the 
development of new vessels from preexisting blood vessels while vasculogenesis is the 
arrangement of new blood vessels from angioblasts, primitive mesodermal cells of the 
primary germ layers committed to differentiate into endothelial cells (Campochiaro, 
2000; Risau and Flamme, 1995). Angioblasts arise from the mesodermal layer during 
embryogenesis in a process called gastrulation (Coffin and Poole, 1988).  During the 
early stages of vasculogenesis, mesodermal angioblasts tightly aggregate near the 
endodermal layer to form a blood band of cells formally known as blood islands (Sabin, 
1920; Vokes and Krieg, 2002; Ferkowicz and Yoder, 2005). The blood band contains a 
collection of outer angioblasts and an inner core of hematopoietic stem cells, called 
hemangioblasts (Murray, 1932; Ferkowicz and Yoder, 2005). The hemangioblasts 
differentiate into angioblasts and then further differentiate into endothelial cells forming 
the lumen and basal lamina of the capillary plexus (Noden, 1990). By late neural plate 
stage, the blood band is 8-15 cells in diameter as it circumferentially wraps around the 
proximal yolk sac with a band thickness of 2-4 cells (Ferkowicz and Yoder, 2005). The 
endothelial cells begin to remodel the blood band into smaller channels with blood cell 
filled capillary beds, connected to the primitive capillary plexus (Sabin, 1920; Risau and 
Flame, 1995; Ferkowicz and Yoder, 2005). A small portion of blood vessels formed 
during embryonic development remain until the adult stage due to primitive vascular 
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plexus regression, thought to be the result of lack of blood perfusion (Risau and Flamme, 
1995). The development of a vasculature during later embryonic and adult stages is 
produced via angiogenesis (Risau and Flamme, 1995).   
Angiogenesis occurs in the yolk sac as well as the developing embryo by 
sprouting from pre-existing vessels and forming a capillary plexus (Risau, 1997). The 
angiogenic process is necessary for normal ovarian function and is stimulated by 
hypoxia, low levels of oxygen, induced by ischemia or lack of adequate blood supply to 
ovarian endothelial cells (Bamberger, 2002; Shweiki, Itin, Neufeld, Gitaygoren, & 
Keshet, 1993). Endothelial cells within the ovary respond within 1-2 hr of hypoxia with 
increased expression of vascular epithelial growth factor (VEGF), an important 
angiogenic signal molecule (Folkman and Klagsbrun, 1987; Folkman, 2003). Once 
VEGF is released and binds to the vascular epithelial growth factor receptor (VEGFR) 
located on adjacent endothelial cells, it has multiple angiogenic roles including inducing 
endothelial cell division, promoting endothelial cells to form vessels by clustering on 
adjacent capillaries, aiding in vascular leakage, and increasing hydraulic conductivity of 
isolated microvessels (Schieki et al., 1993; Risau, 1997; Ferrara, Gerber, & LeCouter, 
2003). Additionally, VEGF promotes the release of matrix metalloproteinase-9 (MMP-9), 
an important extracellular matrix remodeling molecule from endothelial cells which 
causes the degradation of extracellular matrix allowing space for new blood vessel 
formation (Ferrara et al., 2003). Finally, the newly formed endothelial cells adhere and 
create tubes and loops that work as functional vascular units (Ferrera et al., 2003; 
Folkman and Klagsbrun, 1987; Risau, 1997). 
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Ovarian blood vessel formation via vasculogenesis and angiogenesis is not limited 
to embryological phases, but occurs throughout mammalian life (Asahara et al., 1999). 
During adult vasculogenesis, angioblasts from the mesodermal layer are no longer 
involved. Instead, endothelial progenitor cells from the bone marrow circulate through 
the blood, normally in small quantities, and contribute to new blood vasculature (Asahara 
et al., 1999). The bone marrow-derived cells are thought to be recruited by pro-
angiogenic factors, especially VEGF and stromal derived-factor 1 (SDF-1) (De Palma, & 
Naldini, 2006; Li et al., 2006). The circulating endothelial progenitor cells (CEPCs) 
express both VEGFR and chemokine receptors (CXCR4) on their cell surfaces, binding 
to VEGF and SDF-1, respectively (De Palma et al., 2006). The binding of VEGF and 
SDF-1 leads CEPCs to the area of ischemia where they differentiate into endothelial cells 
and form the central region of new blood vessels (Asahara et al., 1999). The total 
contribution of CEPCs appears to be limited to the area of new blood vessel formation 
and does not contribute to fully established adult vasculature (Crosby et al., 2000).  
Furthermore, angiogenesis within the ovary contributes to the remodeling of the early 
blood vasculature previously formed in embryos (Brown and Russell, 2013). The process 
takes place concurrently with folliculogenesis, the development of follicles in the ovary, 
and leutinization, the formation of the corpus luteum after ovulation (Brown and Russell, 
2013; Mosby, 2009). Ovarian angiogenesis is vital for increasing delivery of the 
gonadotropins, luteinizing hormone, follicular stimulating hormone, growth factors, 
oxygen, lipids, and steroid precursors required for folliculogenesis (Brown and Russell, 
5 
 
2013).  Folliculogenesis and luteinization occur in the cortical region of the ovary, 
therefore angiogenesis occurs largely in that area (Fortune et al., 1999).  
Neovascularization via vasculogenesis and angiogenesis returns transplanted 
tissue to a homeostatic environment, reestablishing appropriate blood supply, and is 
proven to be critical for transplantation success (Gourishankar and Halloran, 2002; 
Marzouk, Lawen, Alwayn, & Kiberd, 2013). A major obstacle in the survival of an 
ovarian transplant is vascular failure, which leads to tissue necrosis (Israely et al., 2003). 
Proper blood vascular connection post-transplantation provides important nutrients like 
water, salts, sugars, fats, and proteins, and removes metabolic waste (Cohen, 1945). 
Research utilizing oxygen consumption and terminal deoxynucleotidyl transferase-
mediated dUTP nick end labelling (TUNEL), an apoptosis assay, determined that ovarian 
cortical sections incubated in ischemic minimal essential medium can survive for only 24 
hr without proper blood supply before experiencing significant apoptosis (Kim et al., 
2004).  Additional research examining vascularization of xenograft rat ovaries 
determined ischemia causes medullary tissue damage 24-48 hr after grafting (Israely et 
al., 2003). Therefore, ovarian transplant survival improves when conducted in conditions 
that support vascular maintenance (Israely et al., 2003).   
Recommendations given by Institutional Animal Care and Use Committees 
(IACUC) as well as veterinary medical practitioners are intended to improve recovery, 
reduce the effects of stress, and decrease the amount of pain by providing post-operative 
analgesia for laboratory animals undergoing surgical procedures (Kohn et al., 2007). The 
two main classes of drugs that are recommended for pain management are opioid and 
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non-steroidal anti-inflammatory drugs (NSAIDs).  Within the two analgesic classes, 
meloxicam and buprenorphine are recommended for administration either alone or 
combined depending on the level of pain the host may experience (Kohn et al., 2007). 
The most commonly used analgesic for post-operative care in mice is buprenorphine, 
which is used for moderate to severe pain and has a prolonged duration of analgesic 
action (Gargiulo et al., 2012). Meloxicam has the advantage of being more easily 
consumed orally and is less likely to result in gastrointestinal disturbances (Gargiulo et 
al., 2012; Blaha and Leon, 2008).  While it is vital to ensure proper comfort and pain 
management for laboratory animals undergoing organ transplantation, it is also important 
to evaluate whether either class of drugs could potentially affect vasculogenesis and 
angiogenesis.  
Buprenorphine is an opioid used as an analgesic in both humans and animals 
(Cowan, Doxey, & Harry, 1977). Buprenorphine is a semisynthetic opiate from the 
precursor thebaine and is specific for the OP3/µ receptor, an opioid receptor that has been 
shown to have anti-nociceptive effects, as well as exhibit slow receptor kinetics and 
sustained activation (Garrett and Chandran, 1990; Lutfy et al., 2003). Activating the 
OP3/µ receptor also causes sedation, a drop in blood pressure, and decreased GI motility 
(Johnson, Fudala, & Payne, 2005).  Due to the slow receptor kinetics, buprenorphine is 
considered to be a long-acting analgesic with a low physical dependence (Cowan et al., 
1977; Johnson et al., 2005). 
Research examining the effects of opiate/opioid drugs on angiogenesis has been 
conflicting. Morphine, a commonly used opiate analgesic, has been shown to stimulate 
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microvascular endothelial cell proliferation and angiogenesis in a murine MCF-7 cell 
breast tumor xenograft model in vivo at a dose of 0.714 mg/kg for 15 days followed by a 
dose of 1.43 mg/kg for 23 days (Gupta et al., 2002).  Furthermore, research conducted in 
vitro using a murine matrigel model with 10 µM morphine and 10 µM morphine/10 µM 
naloxone (an opioid antagonist), for 10 days showed similar results (Gupta et al., 2002). 
This research found that an increase in angiogenesis was achieved by activating mitogen-
activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) 
phosphorylation and is dependent on nitric oxide (NO) in microvascular endothelial cells 
(Gupta et al., 2002). Morphine and VEGF have been shown to increase angiogenesis 
through a similar mechanism (Gupta et al., 2002). In a separate study, morphine was 
topically applied to rats that had an open ischemic wound, and after one week morphine 
increased angiogenesis by 45-87% compared to the phosphate buffered saline control 
group (Poonawala, Levay‐Young, Hebbel, & Gupta, 2005). The increased angiogenesis 
and wound healing was explained by up-regulation of VEGF, inducible nitric oxide 
synthase, and the VEGF receptor flk-1 in the wounds (Poonawala et al., 2005).  In a 
conflicting study, mouse heart microvascular endothelial cells treated with morphine-
sulfate at a dose of 100 ng/mL and then incubated for 24 hr in hypoxic conditions, 
showed markedly reduced VEGF expression and reduced Vegf mRNA (Balasubramanian 
et al., 2001). In a similar study, nude mice treated subcutaneously with Lewis lung 
carcinoma cells (LLCs) were given morphine, control, or a morphine/naltrexone 
combination at a dose of 200-400 ng/mL for 7 days, followed by an additional dose of 20 
mg/kg/day for days 7-14, followed by 30 mg/kg/day for days 15-21 (Koodie, 
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Ramakrishnan, & Roy, 2010). These investigators found that morphine reduced vessel 
density, vessel branching, and vessel length.  Additionally, LLCs were administered 1.0 
µmol/L morphine sulfate and grown on tissue-cultured treated dishes and examined for 
VEGF-A expression via real-time PCR (Koodie et al., 2010). This study found a 
significant reduction in tumor cell-induced angiogenesis, VEGF-A expression, vessel 
density, vessel branching, and vessel length with cultured LLCs and mice treated with 
morphine sulfate (Koodie et al., 2010).   
 In addition to opioid derivatives, meloxicam is an NSAID that binds specifically 
to cyclo-oxygenase-2 enzymes (COX-2).  COX-2 plays an important role in 
inflammation by stimulating prostaglandin synthesis (Vane, 1994; Willoughby, Moore, & 
Colville-Nash, 2000). Under the normal inflammatory pathway, arachidonic acid is 
converted to prostaglandin-G2 (PGG2) by COX-1 or COX-2 (Vane, 1994).  PGG2 is 
converted to prostaglandin-H2 (PGH2) by COX-1 or COX-2 (Hamberg, Svensson, & 
Samuelsson, 1975).  PGH2 can undergo five separate conversion pathways that can yield 
several prostanoids (Vane, 1994). Prostanoids function as autocrine and paracrine factors 
that mediate the inflammatory response (Ricciotti and FitzGerald, 2011). Meloxicam and 
other NSAIDs irreversibly acetylate the COX-2 enzyme (Vane, 1994). Research has 
shown that meloxicam, when administered to Wistar rat gingival margins at a dose of 3 
mg/kg/day, intraperitoneally, for 3, 7, 14, and 30 days can serve as an inhibitor to 
angiogenesis by reducing mRNA expression of VEGF, a key angiogenic and 
vasculogenic growth factor (Oliveira et al., 2008). In a separate study, pellets containing 
the pro-angiogenic factor basic Fibroblast Growth Factor (bFGF) were implanted into the 
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cornea of rats (Leahy et al., 2002). Once the pellets were implanted, meloxicam at a dose 
of 30 mg/kg/day or saline was administered by gavage twice per day for four days. After 
four days, the rat corneas showed a significant (78.6%) reduction in angiogenesis due to 
inhibition of the COX-2 enzyme (Leahy et al., 2002). The previous two studies indicate 
the potential for meloxicam and other COX-2 inhibitors to reduce angiogenesis by 
decreasing the production of prostaglandins and the expression of VEGF (Oliveira et al. 
2008; Leahy et al., 2002). 
 Confocal microscopy is widely used for visualization of blood vessels (McDonald 
and Choyke, 2003). It uses a focused laser beam to illuminate a specific focal plane in 
tissue (Webb, 1996). The light that is reflected from that focal point enters through a 
pinhole on the microscope and acts as a size-spatial filter that limits the amount of light 
that eventually returns to the detector (Aghassi, Anderson, & González, 2000). Confocal 
microscopy has the advantage of increased contrast, especially on thick specimen 
microscopic images (McDonald and Choyke, 2003). The advantage of focusing on such a 
small focal plane is the reduction in scattering of out-of-plane light as well as improved 
image contrast and resolution compared to wide field microscopy (Webb, 1996).  
Confocal microscopy can be used for either light or fluorescent microscopy; 
however, it is more commonly used for fluorescent imaging to detect specific cellular 
components (McDonald and Choyke, 2003). Confocal microscopy is often utilized to 
study angiogenesis and vasculogenesis by fluorescently labeling specific cell markers that 
target neovascularization. An important antigen, vital for vascular cell adhesion, is the 
cluster of differentiation-31/platelet endothelial cell adhesion molecule (CD31/PECAM-
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1) (Albelda, Muller, Buck, & Newman, 1991). This particular protein is approximately 
100 amino acids in length and is responsible for the hydrophobic core in protein-protein 
interactions that connects endothelial cells to adjacent endothelial cells during 
neovascularization (DeLisser, Baldwin, & Albelda, 1997; Russell, Breed, & Barton, 
1992).  This specific endothelial antigen has been used to detect postnatal vasculogenesis 
in bone marrow-derived cells, angiogenesis in quail and chicken endothelial cells, and 
microvessel density in breast cancer patients (Asahara, 1999; Kim et al., 2009; Drake, 
Brandt, Trusk, & Little, 1997; Horak et al., 1992).  
Two powerful types of pain relieving medicines, buprenorphine, an opioid, and 
meloxicam, an NSAID, are both widely used and have both shown to affect angiogenesis 
and vasculogenesis. The aim of this study was to examine the impact meloxicam and 
buprenorphine had on ovarian medullary blood vessel formation of aged female recipient 
CBA/J mice transplanted with young ovaries from donor CBA/J mice. Medullary vessel 
analysis was performed by viewing tissue sections fluorescently labelled with specific 
cell marker CD31/PECAM-1 on a confocal microscope. An analysis was performed 
between treatment groups to analyze how the independent variables of analgesic 
administration affected medullary angiogenesis and vasculogenesis by measuring 
multiple dependent variables of deep microvessel quantities.  
Methods and Materials 
Ethics Statement 
This study was conducted in strict accordance with the recommendations in the 
Guide for the Care and Use of Laboratory Animals of the National Institute of Health. All 
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experimental procedures were approved by the Institutional Animal Care and Use 
Committee at San José State University (protocol 959). Surgery was performed under 
sodium pentobarbital anesthesia, and all efforts were made to minimize suffering. 
Animals 
Female recipient CBA/J strain mice (Jackson Laboratory, Sacramento, CA) were 
purchased at seven weeks of age and housed at San José State University. Their housing 
conditions included: five mice per 29 x 22 x 14 cm cage, a daily photoperiod of 12L:12D, 
and ad libitum access to food (Purina Mouse Chow 5008: 23.5% protein, 6.5% fat, Purina 
Mills, St. Louis, MO) and water (Deionized).  Age matched male mice were housed in 
adjacent cages to promote estrous cycling (Whitten, 1956). Two weeks prior to surgery, 
donor mice of the same line were purchased (Jackson Laboratory, Sacramento, CA) at six 
weeks of age and housed under the same living conditions. 
Ovarian Transplantation and Administration of Treatment 
Following surgical procedures previously described by Le, Bonachea, and Cargill 
(2014), female recipient mice, aged to 11 months, were anesthetized with an 
intraperitoneal injection of sodium pentobarbital (0.65 mg/kg of body weight dose, 
Lundbeck Inc., Deerfield, IL) and their ovaries were surgically removed and immediately 
replaced with 2-month old ovaries from CBA/J donor mice (Jackson Laboratory, 
Sacramento, CA) into the ovarian bursae. The ovarian bursa and the abdominal wall were 
closed with 7-0 Ethilon nylon filament and 5-0 Ethicon chromic gut (Ethicon, San 
Angelo, TX), respectively. Wound clips (Becton Dickinson and Company, Sparks, MD) 
were used to close and secure the skin and were removed one week post-surgery. 
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Prior to surgery, recipient mice were randomly assigned to one of three treatment 
groups, meloxicam (Boehringer Ingelheim, St. Joseph, MO), buprenorphine (Reckitt 
Benckiser, Hull, England), or 0.9% saline (Vedco, Inc., St. Joseph, MO) (no analgesic). 
One of the 9 saline mice died during surgery, likely due to an overdose of anesthetic. A 
second saline injected mouse died approximately 1 month post-surgery, most likely due 
to seizures known to affect this line (Fuller, & Sjursen Jr, 1967). This brought the total 
saline injected to a sample size of seven. The mice in the meloxicam treatment group 
animals were administered intraperitoneal doses of 5 mg/kg meloxicam. The 
buprenorphine treatment group animals were administered intraperitoneal doses of 0.05 
mg/kg. The control treatment group animals were administered 0.9% saline in similar 
volumes to the two drug treatment groups. Current veterinary guidelines and 
recommendations as well as previous studies were followed to determine the proper 
doses of analgesics (Mason, Cargill, Anderson, & Carey, 2009; Flecknell, 2009; Plumb, 
2002). The first dose of each treatment was given after ovary allotransplantation and 
before anesthetic recovery. Doses of meloxicam, buprenorphine, and saline were 
administered every 12 hr for 48 hr post-operatively. 
Fixation and Preservation of Ovaries 
For non-biased double-blind analysis all female recipient mice were randomly 
assigned new identification numbers and sacrificed by cervical dislocation between 73-78 
days post-transplantation. One ovary from each mouse was placed in a 5 ml glass vial 
(Wheaton Science Products, Millville, NJ) containing 4 mL of immunohistochemistry 
(IHC) zinc fixative (BD Biosciences, San Diego, CA). After incubation at 4º C for 24 hr, 
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tissue forceps were used to transfer the ovaries to a new vial containing RNase-free 
phosphate buffered saline (PBS) (Boston Bioproducts, Ashland, MA) and secured with 
parafilm. The ovaries were placed in a cardboard container and stored at 4º C.  The 
containers were packed on dry ice in a Styrofoam cooler for shipping. They were shipped 
to IHC World LLC (Ellicott City, MD) for surface CD31 immunohistochemistry staining 
and 3,3’-diaminobenzidine (DAB) chromogen staining.   
Surface CD31 Immunohistochemistry Procedure  
 Upon receipt of samples the 5 ml labeled vials were removed from 4º C and 
ovaries were transferred to labeled 1.5 ml microcentrifuge tubes containing room 
temperature RNase-free PBS (Fisher Scientific, Fair Lawn, NJ).  The ovaries were first 
washed in PBS-Tween20 (Fisher Scientific, Fair Lawn, NJ) for 30 min followed by 
incubation in rabbit anti-mouse CD31 primary antibody (Thermo Scientific Pierce, 
Rockford, IL) diluted 1:100 using IHC-Tek Antibody Diluent (IHC World, Ellicott City, 
MD) on a shaker at room temperature for 16 hr.  Directly after incubation, the ovaries 
were washed in PBS-Tween20 three times for 30 min each and incubated on a shaker in 
3% Peroxidase Blocking Solution (Vector Laboratories, Burlingame, CA) for 20 min at 
room temperature.  This was followed by an additional three washes in PBS-Tween20 for 
30 min each, the ovaries were incubated in biotinylated goat anti-rabbit secondary 
antibody (Thermo Scientific Pierce, Rockford, IL) diluted 1:500 using IHC-Tek Antibody 
Diluent on a shaker at room temperature for 16 hr.  Following this incubation, the ovaries 
were washed in PBS-Tween20 three times for 1 hr each and incubated on a shaker in a 
1:500 dilution of HRP-Streptavidin (Biolegend, San Diego, CA) for 16 hr at room 
14 
 
temperature.  The ovaries were then washed in PBS-Tween20 three times for 1 hr each 
and incubated in a 1:4 dilution of 3,3’-diaminobenzidine (DAB) chromogen (Fisher 
Scientific, Fair Lawn, NJ) for 10-15 min at room temperature, removing the ovaries when 
a uniform dark brown color had been achieved.  Once the ovaries turned the proper color, 
they were rinsed with three washes of PBS-Tween20 at 10 min each and placed in new 
labeled 1.5 ml microcentrifuge tubes containing 1 ml of 50% glycerol (Hampton 
Research, Aliso Viejo, CA) in PBS.  The ovaries were incubated in the 50% 
glycerol/PBS solution for 10-20 min until the ovary sank to the bottom of the tube.  The 
ovaries were then removed and placed in a 70% glycerol in PBS solution and the labeled 
tubes were stored at 4º C.  The ovaries were shipped from IHC World LLC (Ellicott City, 
MD) overnight to San José State University at 4º C. 
Paraffin Embedding   
Upon receipt the ovaries were transferred from the 5 mL labeled vials at 4° C, 
using fine tissue forceps, to new 1.5 mL sterile microcentrifuge tubes containing room 
temperature RNase-free PBS. The ovaries were dehydrated by transfer to 1.5 mL 
microcentrifuge tubes (Fisher Scientific, Fair Lawn, NJ) containing 70% ethanol (Histo-
chem, Jefferson, AR) and placed on a mixer at room temperature for 60 min. This step 
was repeated once with 95% ethanol and twice with 100% ethanol. Finally the ovaries 
were incubated three times with 100% xylene (Sigma-Aldrich, St. Louis, MO) for 1.5 hr 
each at room temperature. After they were removed from the xylene, they were placed 
into a 200 mL beaker containing molten (60º C) paraffin wax (Paraplast Plus, Sigma-
Aldrich) for 2 hr. The ovaries were transferred, using warm sterile forceps, to the well of 
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an embedding cassette (Fisher Scientific, Fair Lawn, NJ). Molten paraffin wax was 
poured into the well of the cassette over the ovary. The ovary and cassette were stored at 
room temperature for 6 hr. After drying, the paraffin embedded ovaries were sectioned 
with a Leica Histoslide 2000 Sliding Microtome (Leica Microsystem, Buffalo Grove, IL). 
Surface ovary sections of 18 µm were used for another experiment. Depending on the 
size of the ovary, surface removal ranged from 108 µm for small ovaries to 378 µm for 
large ovaries. Medullary sections of 40 µm each were mounted on TruBond 380 
microscope slides (TruBond, Woodstock, MD). The slides were air dried for 30 min 
followed by baking at 45º C for 16 hr in a Precision Scientific 25EM oven (Thermo 
Electron Corporation, Marietta, Ohio). Rehydration of the ovary sections was performed 
by three separate washes at room temperature with 100% xylene for 5 min each. The 
slides were immersed one time for 5 min in room temperature 100% ethanol. This step 
was repeated with 95% ethanol, 70% ethanol, and 50% ethanol, respectively. The slides 
were washed twice with RNase-free PBS for 10 min each at room temperature. The slides 
were dried, and any excess PBS was blotted using Kimwipes (Kimberly-Clark, Irving, 
TX).  
Immunofluorescence 
Alexa Fluor fluorescent labeled polyclonal antibody (Abcam) staining was 
performed using the manufacturer protocol (BD Biosciences Franklin Lakes, NJ).  
Briefly, slides were submerged in rabbit polyclonal CD31/PECAM-1 primary antibodies 
(1:50 dilution; Abcam) overnight at 4º C.  The slides were washed two times with room 
temperature PBS for 10 min each. Excess PBS was blotted from the slide using 
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Kimwipes. The slides were incubated for 60 min at room temperature submerged in goat 
anti-rabbit polyclonal secondary antibodies labeled with Alexa Fluor 488 (1:100 dilution; 
Abcam).  The slides were washed twice with PBS for 10 min each. Excess PBS was 
blotted from the slide using Kimwipes. One drop of VECTASHIELD mounting medium 
with 4,6-diamidino-2-phenylindole (DAPI) (Vector Laboratories) was placed on each 
ovary section, which was then topped with a coverslip. 
Deep Microvessel Imaging 
Whole ovary section images were acquired using a Zeiss LSM 700, Axio Imager 
2 confocal microscope with the 20x/0.8 M27 objective. The microscope detection 
wavelength ranges from 493-800 nm with a pinhole size of 27.67 µm. The Alexa Fluor 
488 fluorescent label emitted light that was captured at approximately 519 nm. The 
images were taken in the tile format where the microscope performs a sweeping scan on 
the section taking several images during the sweep. These images were combined to form 
one complete image. The combined image dimensions were 1.92 mm X 1.92 mm. A 
representational image of all three subject groups, at a depth of 328 ± 4 µm, shows the 
intensely illuminated green areas of blood vasculature (Figure 1). The images were 
analyzed using ZEN software (Zeiss, Jena, Germany). The ZEN software circle, line, and 
spine contour graphic tools were used to measure the deep microvessel quantities (Figure 
1). Individual vessels were measured and their data transferred to an excel spreadsheet 
(Microsoft Office, Microsoft Corporation, Redmond, WA). 
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Figure 1. Treatment group Alexa Fluor 488-labeled 40 µm ovary sections. All sections 
are from a depth of 328 µm ± 4 µm. Images are at 200x total magnification. Intensely 
illuminated green areas indicated blood vasculature (white arrow). (A) ovarian section 
from saline treatment group mouse, (B) ovarian section from meloxicam treatment 
mouse, (C) ovarian section from buprenorphine treatment group mouse.  
 
Deep Microvessel Quantification 
The mean number of vessels, diameter of vessels, length of longitudinal vessels, 
number of vessel branches, the length of each branch, number of vessel junctions, surface 
area of the total ovary section, number of branches on a longitudinal vessel, and number 
of junctions per longitudinal vessel were calculated by averaging all measured values 
within each treatment group. 
Statistical Analysis 
The treatment group data was transferred to the SPSS (Version 22.0) computer 
software package (IBM, Armonk, NY). A multivariate analysis of variance (MANOVA) 
was performed between treatment groups to analyze how the independent variables of 
analgesic administration affected multiple dependent variables of deep microvessel 
quantities as listed in the previous section. The MANOVA statistical test is a more 
suitable test for comparing multiple dependent variables that are moderately related 
200x 
A B 
200x 
C 
200x 
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(Cole, Maxwell, Arvey, & Salas, 1993). Data are presented as means ± standard 
deviations. 
Results 
The medullary ovarian vasculature was examined by counting each section of 
tissue for the total number of blood vessels, number of vessels per cross sectional area, 
the number of vessel branches, number of junctions, and the relationship of each 
parameter to overall mean vessel count of all three treatment groups was analyzed. 
Branches are defined as an area where two blood vessels intersect and junctions are 
defined as an area where three or more vessels intersect (Su, Sun, & Pham, 2012) (Figure 
2).  
 
Figure 2. Representative images of meloxicam-treated murine sections. All sections are 
40 µm and the images are at 200x total magnification.  A) Vessel diameter with yellow 
circle indicating the location of a vessel cross section, B) Vessel branching with yellow 
lines represent blood vessel tracing, C) Vessel junction with yellow lines representing 
blood vessel and junctions where three or more vessels combine. 
A summary of the ovarian medullary blood vessel data for all three treatment 
groups is shown in Table 1. None of the medullary blood vessel parameters measured in 
this experiment exhibited a significant difference when compared between treatment 
groups. The average number of blood vessels per section for saline was 20.05 ± 5.15, 
10µm 
C B A 
20µm 50µm 
A B C 
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meloxicam was 24.31 ± 7.15, and buprenorphine was 22.73 ± 8.22 (p = .501). The mean 
vessel density per section for saline was 20.69 ± 11.61 vessel/cm2, meloxicam was 23.99 
± 10.33 vessel/cm2, and buprenorphine was 25.67 ± 16.73 vessel/cm2 (p = .759). The 
mean number of branches in saline was 8.49 ± 3.87, meloxicam was 9.77 ± 2.32, and 
buprenorphine was 7.77 ± 3.83 (p = .454). The mean number of junctions in saline was 
2.67 ± 1.62, meloxicam was 3.56 ± 1.67, and buprenorphine was 2.91 ± 1.51 (p = .512). 
The density of blood vessel branching for saline was 0.412 ± 0.109 branches/vessel, 
meloxicam was 0.430 ± 0.120 branches/vessel, and buprenorphine was 0.333 ± .0902 
branches/vessel (p = .150). The mean number of junctions per vessel for saline was 0.132 
± 0.0624, meloxicam was 0.152 ± 0.0679, and buprenorphine was 0.134 ± 0.0624 (p = 
.772). The mean vessel diameter measured for saline was 12.05 ± 1.44 µm, meloxicam 
was 12.12 ± 0.751 µm, and buprenorphine was 11.31 ± 2.18 µm (p = .500). The mean 
vessel length for saline was 22.45 µm ± 7.30, meloxicam was 25.52 ± 9.93 µm, and 
buprenorphine was 21.53 ± 4.98 µm (p = .530). The mean branch length was measured 
for each treatment group, and the value for saline was 19.30 ± 6.08 µm, meloxicam was 
14.88 ± 5.60 µm, and buprenorphine was 16.10 ± 4.00 µm (p = .253).  
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Table 1.  
Ovarian medullary vasculature quantities 
   
Analgesic Treatment 
 
  
 
Ovarian Medullary Saline Meloxicam Buprenorphine  
Measured Parameters M    ±   SD M    ±    SD M    ±    SD p 
Vessel Count 20.05        5.15 24.32         7.15 22.72         8.23 .501 
Vessel Density 20.69      11.60 23.99       10.33 25.67       16.73 .759 
Vessel Branching 8.49          3.87 9.77          2.32 7.76           3.83 .454 
Vessel Junctions 2.68           1.63 3.57          1.67 2.91           1.51 .512 
Branching Density 0.412       0.109 0.430       0.120 0.333     0.0902 .150 
Vessel Junctions/Vessel 0.132     0.0624 0.152     0.0679 0.134      0.0626 .772 
Vessel Diameter (µm) 12.05        1.44 12.12         0.75 11.31          2.18 .500 
Vessel Length (µm) 22.45       7.29 25.52         9.93 21.53         4.98 .530 
Branch Length (µm) 19.29       6.08 14.88          5.57 16.09          4.00 .253 
Note. Mean, standard deviation, and p-values for mean vessel count, vessel density, 
branching, junctions, branching per unit area, junctions per blood vessel, vessel diameter, 
length, and branch length of medullary ovary sections from saline (n = 7), meloxicam (n 
= 9), and buprenorphine (n = 9) treated females. Each mean represents the average value 
for all ovarian sections within the treatment group. Saline (n = 7), meloxicam (n = 9), and 
buprenorphine (n = 9) treatment groups exhibited no differences in all variables 
measured. 
Discussion 
A vital factor for ovarian transplantation success is the immediate establishment 
of an ample blood supply, which is necessary for the survival of the ovarian follicles and 
prevention of necrosis and apoptosis (Weissman et al., 1999; Eklund, Bry, & Alitalo, 
2013; Starlz, Kaupp, Brock, Lazarus, & Johnson, 1960; Brodie, 1903). Extensive 
revascularization has been shown in juvenile rat ovaries transplanted to an ectopic site 
within 48 hr (Dissen, Lara, Fahrenbach, Costa, & Ojeda, 1994). Before revascularization 
is established, transplants are susceptible to ischemia-reperfusion injury which causes a 
30-70% reduction in graft size due to tissue necrosis (Kim, Soules, & Battaglia, 2002). 
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After ovarian transplantation in mice there is extensive medullary necrotic damage after 
24 hr, with necrosis in almost all the medullary tissue and most of the cortical region 
(Israely et al., 2003). However, transplanted ovaries are able to recover from exhibiting a 
poor quality medullary area three days after transplant to resembling a normal ovary six 
days post-transplant (Israely et al., 2003). An even greater improvement in graft recovery 
and revascularization was realized by injecting endothelial progenitor cells (EPC) and 
VEGF into transplantation sites and inducing adult vasculogenesis (Cha et al., 2014). 
Therefore, under normal and EPC/VEGF injected transplantation conditions, the 
medullary region is capable of recovering from necrosis due to ischemia and is able to 
fully function. 
Since tissue health is dependent on the duration of ischemia, any inhibition of 
blood vessel formation could be detrimental to transplantation success (Kim et al., 2004; 
Starlz et al., 1960). Analgesics can alter angiogenesis and vasculogenesis, and analgesics 
can have a negative impact on ovarian transplantation. In order for the ovarian medulla to 
remain viable, oxygenated blood must be returned within 24-48 hr (Israely et al., 2003). 
Any factor that slows the delivery of oxygenated blood to the medulla can result in tissue 
necrosis. In the present study, the vasculature was severed during surgery, and as a result, 
meloxicam and buprenorphine were not carried to the ovary through the blood by means 
of the ovarian artery branching and entering the medulla and eventually entering the 
cortex of the ovary (Kikuta et al., 1991). On the contrary, meloxicam and buprenorphine 
would need to diffuse through the outer cortex before reaching the deeper medulla of the 
transplanted ovary. Since the analgesic protocol in this current research administered the 
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treatment every 12 hr for the first 48 hr after surgery, the treatment analgesics would have 
needed to penetrate, via diffusion, deep into the medulla during that time to potentially 
influence angiogenesis (Le et al., 2014; Mason et al., 2009). It is unlikely for meloxicam 
(MW = 351 g/mol) and buprenorphine (MW = 467 g/mol) to diffuse from the outer 
cortical regions to the deeper medullary regions, ranging from 200-580 µm in depth, 
during the 48 hr of periodic administration. 
Meloxicam and buprenorphine have been shown to effect neovascularization 
(D'Albora, Anesetti, Lombide, Dees, & Ojeda, 2002; Gupta et al., 2002). Meloxicam is 
an NSAID that has been shown to reduce angiogenesis by specifically inhibiting COX-2 
and decreasing vessel sensitivity to bradykinins and histamines, which reverses 
vasodilation in the inflammatory response, or by reducing the expression of VEGF 
(Katzung, Masters, & Trevor, 2009; Oliveira et al., 2008). Buprenorphine’s targets are 
opioid receptors, specifically OP3 on neurons in the central and peripheral nervous 
system, neuroendocrine, immune, and ectodermal cells (Nalini, Smith, & Manchikanti, 
2011). During development the ovaries are equipped with a network of intrinsic neurons, 
and the medullary region contains neurons most often observed close to blood vessels 
(D’Albora et al., 2002). The function of these neurons is still being investigated. They 
have been shown to produce nitric oxide (NO) and respond to the neurotransmitters 
neuropeptide-Y and catecholamines (D’Albora et al., 2002). The roles of neurons 
responsive to neurotransmitters and catecholamines are thought to be regulative on 
ovarian physiology, and the NO produced by ovarian neurons has been shown to inhibit 
steroidogenesis through autocrine signaling and promote local vasodilation by paracrine 
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signaling (D’Albora et al., 2002). Previous research examining the expression of 
peripheral opioid receptors demonstrated the OP3 receptors are expressed on neurons in 
the ovaries of rats (Wittert, Hope, & Pyle, 1996) This indicates that the specific receptor 
for buprenorphine is present in ovarian tissue. The physiological role of these receptors in 
the medulla of the ovary is still being investigated, however, the results of this study did 
not find any evidence of a regulatory role in vessel formation via angiogenesis or 
vasculogenesis post-ovarian transplantation under the current administration protocol. 
The previously reported literature on the angiogenic effects of meloxicam and 
buprenorphine have been conflicting.  Gupta and colleagues (2002) showed that 
morphine promoted endothelial microvessel growth. Their study examined human breast 
cancer xenografts, by using cell cultures and mammary fat pad and determined that 
morphine activates the MAPK/ERK and NO-dependent pathways to promote 
angiogenesis (Gupta et al., 2002). In a separate study, Balasubramanian et al. (2001) 
found that morphine-sulfate markedly reduces the expression of VEGF and inhibited 
vascular growth. Their research used cell cultured cardiomyocytes and examined VEGF 
mRNA levels to show how morphine-sulfate inhibited angiogenesis and vasculogenesis 
(Balasubramanian et al., 2001). Meloxicam administered to Wistar rat gingival margins 
showed a decrease in angiogenesis by reducing mRNA expression (Oliveira et al., 2008). 
The finding of the previously mentioned studies are inconsistent and conflict with this 
current research. The results in the current study did not indicate medullary endothelial 
microvessel growth nor reduction in the meloxicam or buprenorphine treated mice. A 
possible explanation for these differences may be due to the fact that different tissue 
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types were used in each study. Gupta et al., Balasubramanian et al., and Oliveira et al. all 
examined superficial tissue while this study measured deep medullary vasculature. 
Higher percentages of angiogenesis is expected in superficial regions like the cortex 
versus deeper medullary regions (Cursiefen, Kuchle, & Naumann, 1998; Kang et al., 
2001). The cortical region of the ovary exhibits greater angiogenesis and is closer to any 
potential blood supply from the host. Consequently, the analgesic treatments 
administered would have to penetrate significantly deeper into the ovarian tissue to 
exhibit a significant angiogenic influence on the deep medullary region.    
A factor limiting the concentration of analgesics reaching the ovarian medulla is 
the elimination pharmacokinetics of meloxicam and buprenorphine in tissue. Meloxicam, 
when given to mice intravenously at 10 mg/kg is almost completely eliminated after 24 hr 
(Busch et al., 1998). Analysis of tissue distributions in rats that were given IV meloxicam 
at 1 mg/kg/day for five days and then examined by whole-body autoradiograph showed 
meloxicam was concentrated at moderate levels in the kidneys, skin, lungs, and intestinal 
tract and low levels in the skeletal muscle and central nervous system (Busch et al., 
1998). Buprenorphine when given at 2.4 mg /kg by IV injection showed a half-life of 2.9 
hr and almost complete elimination after 24 hr (Yu, Yue, Cui, & Gong, 2006). Since 
buprenorphine and meloxicam after IV administration are eliminated within 24 hr and 
have half-lives of 2.9 and 6.8 hr, respectively, this could have consequences for the 
concentration of analgesics in the ovarian medulla. 
 Tissue ischemia to the medulla and the cortical ovarian regions occurs during 
transplantation. However, under normal transplantation conditions both regions are 
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capable of recovering from necrosis, with angiogenesis primarily taking place in 
superficial regions like the cortex and not in deeper medullary regions. Analgesics have 
been shown to alter angiogenesis and vasculogenesis; consequently analgesics can have a 
negative impact on ovarian transplantation. Meloxicam and buprenorphine have been 
shown to effect neovascularization, and receptors for buprenorphine are present in 
ovarian neuronal tissue. Still, the previously reported literature has been conflicting and is 
inconsistent with this research. The findings of this study indicate that meloxicam and 
buprenorphine treatments did not promote or inhibit angiogenesis in the medullary region 
of the ovary post-transplantation in aged recipients under the current administration 
protocol.  Several factors need to be examined to determine the disparity between 
findings, such as the pharmacokinetics of the analgesics and their ability to reach 
medullary regions with severed vascular connections.  
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